Skip to main content
Midas Edge

IOVANCE BIOTHERAPEUTICS, INC.

For the period ended Dec 31, 2025. Filed Feb 24, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 24, 2026

IOVA$8.08-1.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

(In thousands, except share information)

​​​​​​​​​​​​​​​​​​​​​​​​​​​​
​ · ​ · Series A · ​ · Series B · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​ · ​
​ · ​ · Convertible · ​ · Convertible · ​ · ​ · ​ · ​ · ​ · ​ · Additional · ​ · Accumulated Other · ​ · ​ · ​ · ​ · Total
​ · ​ · Preferred Sock · ​ · Preferred Stock · ​ · Common Stock · ​ · Paid-In · ​ · Comprehensive · ​ · Accumulated · ​ · Stockholders’
​ · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Shares · ​ ​ ​ · Amount · ​ ​ ​ · Capital · ​ ​ ​ · Income · ​ ​ ​ · Deficit · ​ ​ ​ · Equity
Balance - December 31, 2022​194​$—​2,842,158​$3​187,812,072​$8​$2,068,867​$(902)​$(1,568,338)​$499,638
Stock-based compensation expense​—​​—​—​​—​—​​—​​62,625​​—​​—​​62,625
Vesting of restricted shares issued for services​—​​—​—​​—​1,253,465​​—​​—​​—​​—​​—
Tax payments related to shares retired for vested restricted stock units​—​​—​—​​—​(454,367)​​—​​(2,795)​​—​​—​​(2,795)
Common stock issued upon purchase of employee stock purchase plan​—​​—​—​​—​435,459​​—​​2,410​​—​​—​​2,410
Common stock issued upon exercise of stock options​—​​—​—​​—​8,860​​—​​63​​—​​—​​63
Common stock sold in public and/or at the market offering, net of offering costs​—​​—​—​​—​67,080,226​​3​​463,278​​—​​—​​463,281
Unrealized gain on investments​—​​—​—​​—​—​​—​​—​​940​​—​​940
Foreign currency cumulative translation adjustment​—​​—​—​​—​—​​—​​—​​2,488​​​​​2,488
Net loss​—​​—​—​​—​—​​—​​—​​—​​(444,037)​​(444,037)
Balance - December 31, 2023​194​$—2,842,158​$3256,135,715​$11​$2,594,448​$2,526​$(2,012,375)​$584,613
​​​​​​​​​​​​​​​​​​​​​​​​​​​​
Balance - December 31, 2023194​$—2,842,158​$3256,135,715​$11​$2,594,448​$2,526​$(2,012,375)​$584,613
Stock-based compensation expense​—​​—​—​​—​—​​—​110,877​​—​​—​110,877
Vesting of restricted shares issued for services​—​​—​—​​—​3,150,172​​—​​—​​—​​—​​—
Tax payments related to shares retired for vested restricted stock units​—​​—​—​​—​(1,098,388)​​—​​(12,858)​​—​​—​​(12,858)
Common stock issued upon purchase of employee stock purchase plan​—​​—​—​​—​497,044​​—​​2,952​​—​​—​2,952
Common stock issued upon exercise of stock options​—​​—​—​​—425,925​—​3,266​​—​​—​3,266
Common stock sold in public and/or at the market offering, net of offering costs​—​​—​—​​—​46,141,726​​2​​397,302​​—​​—​397,304
Unrealized gain on investments​—​​—​—​​—​—​​—​​—​78​​—​​78
Foreign currency cumulative translation adjustment​—​​—​—​​—​—​​—​​—​​(3,650)​——​​(3,650)
Net loss​—​​—​—​​—​—​​—​​—​​—​(372,177)​​(372,177)
Balance - December 31, 2024194​$—2,842,158​$3305,252,194​$13​$3,095,987​$(1,046)​$(2,384,552)​$710,405
​​​​​​​​​​​​​​​​​​​​​​​​​​​​
Balance - December 31, 2024194​$—2,842,158​$3305,252,194​$13​$3,095,987​$(1,046)​$(2,384,552)​$710,405
Stock-based compensation expense​—​​—​—​​—​—​​—​60,897​​—​​—​60,897
Vesting of restricted shares issued for services​—​​—​—​​—5,136,198​—​—​​—​​—​—
Tax payments related to shares retired for vested restricted stock units​—​​—​—​​—​(2,058,144)​​—​(7,059)​​—​​—​(7,059)
Common stock issued upon purchase of employee stock purchase plan​—​​—​—​​—​796,402​​—​​1,510​​—​​—​​1,510
Common stock issued upon exercise of stock options​—​​—​—​​—2,586​—​15​​—​​—​15
Common stock sold in public and/or at the market offering, net of offering costs​—​​—​—​​—​101,899,334​​4​​306,303​​—​​—​​306,307
Common stock issued from preferred stock conversion​—​​—​(909,491)​​(1)​909,491​​—​​1​​​​​​​​—
Unrealized loss on investments​—​​—​—​​—​—​​—​​—​(54)​​—​(54)
Foreign currency cumulative adjustments​—​​—​—​​—​—​​—​​—​​17,540​​—​​17,540
Net loss​—​​—​—​​—​—​​—​​—​​—​(390,978)​(390,978)
Balance - December 31, 2025194​$—1,932,667​$2411,938,061​$17​$3,457,654​$16,440​$(2,775,530)​$698,583
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.